- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on PDL BioPharma Inc. (PDLI)
by latest | most commented
-
Smaller Pharma Wins the 'Most Valuable' Race
-
23 High Quality, High Dividend Stocks
-
Klarman's Baupost Group Bets Big on Capitalsource, News Corp.
-
PDL BioPharma: Past, Present and Future
-
What Does Seth Klarman See in Facet Biotech?
-
Seth Klarman's Best Ideas (for Now)
-
10 Hedge Fund Best Ideas
-
15 Value Hedge Funds - Portfolio Update
-
Bristol-Myers Ponies Up for Elotuzumab
-
Seth Klarman, Meryl Witmer and Marty Whitman - Q2 2008 Portfolio Moves
-
Top Holdings of the Top Hedge Fund Earners Last Year
-
Last Week's Winners and Losers
-
Friday's Options Report: C, WM, CCJ, LNG, PDLI, LTD
-
Healthcare Stocks Have Been Anything but Defensive
-
Wednesday's Options Report: TIBX, NUAN, DFS, XLF, PDLI, ORCL, XLK
-
Highland Capital Wants PDL BioPharma To Hire New Advisor
-
Loeb Says Goodbye to PDL BioPharma
-
PDL BioPharma: Loeb's Third Point Lowers Stake to 5.1%
-
PDL BioPharma Yields To Activists, Stock Jumps
-
Highland Capital Joins Loeb In Calling For a Sale of PDL BioPharma
-
Activist Target PDL BioPharma Under Fire; Loeb And Others Raise the Heat
-
PDL Biopharma: Shorting Above $19 is a Safe Bet
-
PDL BioPharma: Loeb Finally Gets CEO McDade's Head
-
Loeb's Third Point Issues Latest 13F: Summary of Holdings
-
PDL BioPharma: Loeb's Third Point Reiterates Demand to Terminate CEO
-
PDL BioPharma: Is CEO McDade On the Way Out?
-
PDL BioPharma: Loeb's Third Point Wants Chairman Dismissed
-
Four Cheap Biotech Stock Picks: Amgen, Aspreva, Exelixis, PDL Biopharma
-
PDL BioPharma: Co-Founder Queen Supports Third Point's Proposals
-
PDL BioPharma: Loeb Reiterates Demand For CEO McDade's Resignation
-
Hedge Fund Increases Heat On PDL BioPharma CEO
-
PDL BioPharma: Loeb's Third Point Wants CEO McDade Out
-
What Does Third Point See in PDL Biopharma?
-
PDL BioPharma: Third Point Raises Stake, Requests Four Seats on Board
-
Biotech Day in Review: Schering-Plough Buys Organon for $14.4 Billion
-
Indirect Investing Opportunities in Different Industries
-
PDL BioPharma: Third Point Raises Stake, Urges Company to Cut Costs
-
Genentech 4th Quarter Report Leads Biotech Rally
-
PDL Biopharma: Troubled Summer, But Holding On
-
Biotech Portfolio Overview: PDL Biopharm Still Cheap, CV Therapeutics Still Falling
-
Analyst Upgrades & Downgrades for Monday July 24, 2006